Department of Clinical Oncology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo 113-8510, Japan.
Department of Clinical Research, National Hospital Organization Disaster Medical Center, Tokyo 190-0014, Japan.
Curr Oncol. 2023 Jul 7;30(7):6546-6558. doi: 10.3390/curroncol30070480.
Colorectal cancer (CRC) is the second most common cause of cancer-related deaths worldwide. The 5-year survival rate after curative resection is almost 80%, however, it is still less than satisfactory for metastatic CRC (mCRC). The combination approach including surgery, chemotherapy, molecular targeted therapy, and immunotherapy is a promising strategy due to its synergistic anticancer effect. Moreover, circulating tumor DNA (ctDNA) analysis has been reported to stratify the post-operative risk of recurrence, thus providing clinically valuable information for deciding to conduct adjuvant chemotherapy. Furthermore, multiple new drugs that potentially target undruggable genes, including have been developed. In this review, we discuss the current management of patients with mCRC and future perspectives in the light of a combination therapeutic strategy.
结直肠癌（CRC）是全球癌症相关死亡的第二大主要原因。经过根治性切除术后的 5 年生存率接近 80%，然而转移性结直肠癌（mCRC）的生存率仍然不尽人意。包括手术、化疗、分子靶向治疗和免疫治疗在内的联合治疗方法具有协同抗癌作用，是一种很有前途的策略。此外，循环肿瘤 DNA（ctDNA）分析已被报道可对术后复发风险进行分层，从而为决定是否进行辅助化疗提供了有临床价值的信息。此外，还开发了多种新的药物，这些药物可能靶向潜在的不可用药基因，包括 。在这篇综述中，我们根据联合治疗策略讨论了 mCRC 患者的当前治疗方法和未来前景。
